Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lung Neoplasms 76Leukemia, Myeloid, Acute 68Prostatic Neoplasms 66Carcinoma, Non-Small-Cell Lung 56Neoplasm Metastasis 55Breast Neoplasms 51Multiple Myeloma 42Colorectal Neoplasms 40Pancreatic Neoplasms 33Carcinoma, Renal Cell 33Myelodysplastic Syndromes 31Melanoma 31Leukemia, Lymphocytic, Chronic, B-Cell 29Triple Negative Breast Neoplasms 28Ovarian Neoplasms 27Lymphoma, Large B-Cell, Diffuse 25Glioblastoma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Urinary Bladder Neoplasms 22Lymphoma 22Burkitt Lymphoma 21Squamous Cell Carcinoma of Head and Neck 20Carcinoma, Hepatocellular 19Glioma 18Fallopian Tube Neoplasms 18Endometrial Neoplasms 17Oropharyngeal Neoplasms 15Mouth Neoplasms 15Lymphoma, Follicular 15Leukemia, Biphenotypic, Acute 15

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Serous Adenocarcinoma × Specimen Handling × 1 year × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡